Recognizing the evolution of clinical syndrome spectrum progression in individuals with single large-scale mitochondrial DNA deletion syndromes (SLSMDS)
- 19 February 2025
- journal article
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (5) , 101386
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Larimar Therapeutics
- Astellas Pharma US
This publication has 33 references indexed in Scilit:
- Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial diseaseJournal of Inherited Metabolic Disease, 2020
- Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literatureAmerican Journal of Medical Genetics Part A, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Mitochondrial Genomics: A Complex Field Now Coming of AgeCurrent Genetic Medicine Reports, 2018
- Growth differentiation factor 15 as a useful biomarker for mitochondrial disordersAnnals of Neurology, 2015
- Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of diseaseJournal of Inherited Metabolic Disease, 2014
- The PedsQL™ Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infantsQuality of Life Research, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Detection and characterization of mitochondrial DNA rearrangements in Pearson and Kearns-Sayre syndromes by long PCRHuman Genetics, 1997
- The measurement of performance in childhood cancer patientsCancer, 1987